SELLAS Life Sciences Group, Inc. Common Stock
SLSSELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company's portfolio includes treatments designed to enhance the immune system's ability to recognize and destroy cancer cells, with an emphasis on innovative approaches to immuno-oncology. SELLAS aims to address unmet medical needs through its research-driven pipeline and strategic collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 5, 2011 | $0.24 | 2011-03-24 | 2011-03-28 |
| December 20, 2010 | $0.42 | 2010-12-09 | 2010-12-13 |
| September 22, 2010 | $0.15 | 2010-09-09 | 2010-09-13 |
| June 21, 2010 | $0.09 | 2010-06-10 | 2010-06-14 |
| March 29, 2010 | $0.09 | 2010-03-18 | 2010-03-22 |
Dividends Summary
- Consistent Payer: SELLAS Life Sciences Group, Inc. Common Stock has rewarded shareholders with 11 dividend payments over the past 3 years.
- Total Returned Value: Investors who held SLS shares during this period received a total of $2.54 per share in dividend income.
- Latest Payout: The most recent dividend of $0.24/share was paid 5407 days ago, on April 5, 2011.
- Yield & Schedule: SLS currently pays dividends quarterly with an annual yield of 20.20%.
- Dividend Growth: Since 2008, the dividend payout has decreased by 45.1%, from $0.44 to $0.24.
Company News
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
SELLAS presented preclinical data showing that its CDK9 inhibitor SLS009 demonstrated potent anti-proliferative activity in ASXL1 mutant colorectal cancer cell lines, suggesting its potential as a targeted therapy for this patient population.
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.
